XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Operating activities    
Net income $ 157,360 $ 147,220
Adjustments to reconcile net income to net cash provided by operating activities:    
Distributions from unconsolidated subsidiaries 13,609 10,734
Depreciation and amortization 160,072 149,022
Provision for bad debts 2,344 (373)
Equity in earnings of unconsolidated subsidiaries (18,710) (14,914)
Loss on extinguishment of debt 10,160 484
Gain on sale of assets and businesses (6,349) (9,129)
Stock compensation expense 19,431 17,175
Amortization of debt discount, premium and issuance costs 9,469 9,845
Deferred income taxes (7,247) (2,092)
Changes in operating assets and liabilities, net of effects of business combinations:    
Accounts receivable (93,425) 23,495
Other current assets (6,016) (10,274)
Other assets 1,259 4,828
Accounts payable 1,369 (3,507)
Accrued expenses 22,396 49,391
Income taxes 918 9,072
Net cash provided by operating activities 266,640 380,977
Investing activities    
Business combinations, net of cash acquired (86,269) (519,258)
Purchases of property and equipment (123,956) (121,039)
Investment in businesses (60,668) (12,936)
Proceeds from sale of assets and businesses 183 6,691
Net cash used in investing activities (270,710) (646,542)
Financing activities    
Borrowings on revolving facilities 700,000 420,000
Payments on revolving facilities (720,000) (585,000)
Proceeds from term loans 593,683 779,904
Payments on term loans (375,084) (8,625)
Proceeds from 6.250% senior notes 539,176 0
Payment on 6.375% senior notes 710,000 0
Revolving facility debt issuance costs (310) (1,333)
Borrowings of other debt 19,282 30,134
Principal payments on other debt (22,628) (17,971)
Repurchase of common stock (37,309) (5,640)
Proceeds from exercise of stock options 872 1,633
Decrease in overdrafts (25,083) (6,172)
Proceeds from issuance of non-controlling interests 18,288 2,926
Distributions to and purchases of non-controlling interests (16,032) (306,427)
Net cash provided by (used in) financing activities (35,145) 303,429
Net increase (decrease) in cash and cash equivalents (39,215) 37,864
Cash and cash equivalents at beginning of period 175,178 122,549
Cash and cash equivalents at end of period 135,963 160,413
Supplemental Information    
Cash paid for interest 149,090 134,378
Cash paid for taxes 58,472 40,460
Non-cash equity exchange for acquisition of U.S. HealthWorks $ 0 $ 238,000